Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.
Artemisinin resistance in Plasmodium falciparum threatens to reduce the efficacy of artemisinin combination therapies (ACTs), thus compromising global efforts to eliminate malaria. Recent treatment failures with dihydroartemisinin-piperaquine, the current first-line ACT in Cambodia, suggest that pip...
Main Authors: | Amaratunga, C, Lim, P, Suon, S, Sreng, S, Mao, S, Sopha, C, Sam, B, Dek, D, Try, V, Amato, R, Blessborn, D, Song, L, Tullo, G, Fay, M, Anderson, J, Tarning, J, Fairhurst, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Lancet
2016
|
Similar Items
-
Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study
by: Amaratunga, C, et al.
Published: (2016) -
Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study
by: Kwiatkowski, D, et al.
Published: (2016) -
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
by: van Der Pluijm, R, et al.
Published: (2019) -
Treatment failure of dihydroartemisinin/piperaquine for plasmodium falciparum malaria, Vietnam
by: Phuc, B, et al.
Published: (2017) -
Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment
by: Leang, R, et al.
Published: (2015)